{"id":"https://openalex.org/W2283964571","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","title":"Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102\u2014Final report.","display_name":"Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102\u2014Final report.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2283964571","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","mag":"2283964571"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.3587","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091389881","display_name":"Safi Shahda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Shahda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057063597","display_name":"Menggang Yu","orcid":"https://orcid.org/0000-0002-7904-3155","observed_orcids":["https://orcid.org/0000-0002-7904-3155"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Yu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034354367","display_name":"Joel Picus","orcid":"https://orcid.org/0000-0002-4038-936X","observed_orcids":["https://orcid.org/0000-0002-4038-936X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Picus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034507738","display_name":"Jos\u00e9 A. Bufill","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. A. Bufill","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967040","display_name":"Wael A. Harb","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. A. Harb","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101982540","display_name":"Matthew Burns","orcid":"https://orcid.org/0009-0004-6328-9953","observed_orcids":["https://orcid.org/0009-0004-6328-9953"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Burns","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012011099","display_name":"Aaron John Spittler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. J. Spittler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004501443","display_name":"Janet Flynn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Flynn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Y. Zeng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Zeng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086286601","display_name":"Gail H. Vance","orcid":"https://orcid.org/0000-0002-7424-2921","observed_orcids":["https://orcid.org/0000-0002-7424-2921"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. H. Vance","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046088154","display_name":"Jingwei Wu","orcid":"https://orcid.org/0000-0003-1003-619X","observed_orcids":["https://orcid.org/0000-0003-1003-619X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Wu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111777690","display_name":"C. R. Currie","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. R. Currie","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021904320","display_name":"Patrick Joseph Loehrer","orcid":"https://orcid.org/0000-0002-1532-4660","observed_orcids":["https://orcid.org/0000-0002-1532-4660"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. J. Loehrer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5019995834","display_name":"Elena Gabriela Chiorean","orcid":"https://orcid.org/0000-0003-3306-9592","observed_orcids":["https://orcid.org/0000-0003-3306-9592"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. G. Chiorean","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"3587","last_page":"3587"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9649999737739563},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9900000095367432},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8659999966621399},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.7570000290870667},{"id":"https://openalex.org/keywords/egfr-inhibition","display_name":"EGFR inhibition","score":0.9779999852180481},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6359999775886536},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8500000238418579},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9739999771118164},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.6629999876022339},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8460000157356262},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.8009999990463257},{"id":"https://openalex.org/keywords/egfr-phosphorylation","display_name":"EGFR phosphorylation","score":0.5960000157356262},{"id":"https://openalex.org/keywords/mtor-phosphorylation","display_name":"mTOR phosphorylation","score":0.8289999961853027},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.4560000002384186},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.5559999942779541},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.7850000262260437}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9358177781105042},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.6696064472198486},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6490313410758972},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.6336648464202881},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.6073166131973267},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5995627641677856},{"id":"https://openalex.org/C2779998722","wikidata":"https://www.wikidata.org/wiki/Q420296","display_name":"Cetuximab","level":4,"score":0.5796618461608887},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5693553686141968},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.5605813264846802},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.5599004030227661},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5082842707633972},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.48509085178375244},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.47881656885147095},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.42442014813423157},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4175558090209961},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.38948124647140503},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3243722915649414},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.31031399965286255}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.3587","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3587","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2590430893","https://openalex.org/W2599669129","https://openalex.org/W1777027747","https://openalex.org/W2801056424","https://openalex.org/W2240403613","https://openalex.org/W4238735537","https://openalex.org/W2564696255","https://openalex.org/W2588612263","https://openalex.org/W2737025902","https://openalex.org/W2591488768"],"abstract_inverted_index":{"3587":[0],"Background:":[1],"Preclinically,":[2],"mTOR":[3,13,156],"and":[4,35,46,73,85,124,130,144,155,198,218,230,304,308,314,316,343],"EGFR":[5,154],"inhibitors":[6],"are":[7,234],"synergistic.":[8],"We":[9],"hypothesize":[10],"that":[11,272],"the":[12,33,107],"inhibitor":[14],"RAD001":[15,42,77,139,262,275,333,355],"would":[16],"enhance":[17],"clinical":[18],"efficacy":[19],"when":[20],"added":[21],"to":[22,31,111,128,134,203,271],"C.":[23,135],"The":[24,102,238,330],"main":[25],"purpose":[26],"of":[27,40,76,153,232,332,334],"this":[28],"study":[29,103,349],"was":[30,104,140,267],"determine":[32],"safety,":[34],"maximum":[36],"tolerated":[37],"dose":[38],"(MTD)":[39,387],"daily":[41],"combined":[43],"with":[44,54,92,222,274,338],"Iri":[45,55,217],"C":[47,65,219],"in":[48,236,292],"mCRC.":[49,101],"Methods:":[50],"Pts":[51],"were":[52,147,162,208,244,284,306],"treated":[53],"125":[56],"mg/m2":[57,67,71],"weekly":[58],"(qw)":[59],"x":[60],"2":[61,368,376,386,400,404,406,416],"every":[62],"3":[63,206,216,370,373,395,402,414],"wks,":[64],"400":[66],"loading,":[68],"then":[69],"250":[70],"qw,":[72],"escalating":[74],"doses":[75],"orally:":[78],"5":[79,82,335,365,380,389,393,409],"mg":[80,83,87,336,366,381,390,398,410],"qod,":[81],"qd":[84,88],"10":[86,397],"during":[89],"21-day":[90],"cycles,":[91],"a":[93],"\u201c3+3\u201d":[94],"design.":[95],"Eligibility":[96],"allowed":[97],"KRAS":[98,293,312,320],"mutated":[99],"(MUT)":[100],"amended":[105],"after":[106],"first":[108],"9":[109,299],"pts*,":[110],"include":[112],"stopping":[113],"rules":[114],"for":[115,121,138,149,183,211,280,296,311,319],"excessive":[116],"toxicity":[117],"beyond":[118],"expected":[119],"rates":[120],"diarrhea,":[122],"nausea/vomiting":[123],"febrile":[125,258,374],"neutropenia":[126,259,375],"due":[127,133,213],"Iri,":[129],"skin":[131],"rash":[132,247],"PK":[136],"(Cmin)":[137],"done":[141],"on":[142],"C2D1,":[143],"archival":[145],"tumors":[146],"analyzed":[148],"pharmacodynamic":[150],"(PD)":[151],"markers":[152,325],"pathway":[157],"activation.":[158],"Results:":[159],"30":[160],"pts":[161,207,278],"enrolled":[163],"(KRAS":[164],"WT":[165],"12;":[166],"MUT":[167,294,321],"15;":[168],"unknown":[169],"3),":[170],"median":[171,361],"age":[172],"60.5":[173],"y":[174],"(25-77),":[175],"16":[176],"male,":[177],"ECOG":[178],"PS":[179],"0/1":[180],"(20/10).":[181],"Reasons":[182],"treatment":[184],"discontinuation":[185],"were:":[186],"PD":[187,324],"(13),":[188],"adverse":[189],"events":[190],"(AEs)":[191],"(8),":[192],"pt":[193,295],"withdrawal":[194],"(2),":[195],"symptomatic":[196],"deterioration":[197],"non-compliance":[199,227],"(1":[200,225],"each).":[201,261],"Prior":[202],"study\u2019s":[204],"amendment*,":[205],"not":[209],"evaluable":[210,279],"DLT":[212,357,358],"to:":[214],"gr":[215,241],"infusion":[220,224],"reactions":[221],"1st":[223],"each),":[226,253],"(1).":[228],"DLTs":[229],"number":[231],"cycles":[233],"listed":[235],"Table.":[237],"most":[239],"common":[240],"3/4":[242],"AEs":[243],"diarrhea":[245,371,415],"(9),":[246],"(6),":[248],"mucositis,":[249],"ANC,":[250],"fatigue":[251],"(4":[252],"nausea":[254],"(3),":[255],"vomiting,":[256],"anorexia,":[257],"(2":[260],"mean":[263],"Cmin":[264],"at":[265],"MTD":[266,331],"8.5":[268],"ng/mL,":[269],"similar":[270],"seen":[273],"alone.":[276],"Among":[277],"response":[281],"(n=24),":[282],"there":[283],"1":[285,378,412],"CR,":[286],"4":[287],"PR":[288],"(21%,":[289],"including":[290],"1PR":[291],"26":[297],"mos),":[298],"SD":[300],"(37%).":[301],"Median":[302],"PFS":[303],"OS":[305],"6":[307,384],"28":[309],"mos":[310,318],"WT,":[313],"3.3":[315],"12":[317],"pts,":[322],"respectively.":[323],"will":[326],"be":[327],"presented.":[328],"Conclusions:":[329],"QD":[337,391,399,411],"Iri/C":[339],"qw":[340],"is":[341,350],"safe":[342],"clinically":[344],"active.":[345],"A":[346],"phase":[347],"II":[348],"ongoing.":[351],"Cohort":[352],"(#":[353],"pts)":[354],"#":[356,359],"Cycles":[360],"(range)":[362],"1*":[363],"(9)":[364],"QOD":[367,382],"Gr":[369,372,401,413],"(1-34)":[377],"(3)":[379],"0":[383,392],"(2-10)":[385],"(4)":[388,396],"(1-13)":[394],"mucositis":[403],"(2-6)":[405],"expansion":[407],"(10)":[408],"(1-9+)":[417]},"counts_by_year":[{"year":2018,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}